Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: FEBS J. 2013 Apr 8;280(9):10.1111/febs.12226. doi: 10.1111/febs.12226

Fig. 3.

Fig. 3

EGFR/PI3K/AKT pathway regulates CSC phenotype in NPC. (A) CNE1 and CNE2 cells were treated with indicated inhibitors for 24 h followed by FACS SP analyses. EGF (50 ng/mL)-induced SP cells were diminished by EGFR inhibitor (either 1 μM of gefitinib or 0.5 μM PD153035) or PI3K inhibitor LY294002 (15 μM), but not by Mek inhibitor PD0325901 (10 μM). Data are presented as mean ± SD (n = 3). *, P< 0.01; **, P> 0.05. (B) Cells were treated as described in (A) followed by Western blot analysis. EGF-induced phosphorylation of EGFR, AKT and ERK1/2 was blocked by gefitinib or PD153035.